Cryolife (CRY) Downgraded to Buy at ValuEngine

ValuEngine downgraded shares of Cryolife (NYSE:CRY) from a strong-buy rating to a buy rating in a research report report published on Wednesday morning, ValuEngine reports.

A number of other research firms also recently weighed in on CRY. Needham & Company LLC reissued a hold rating on shares of Cryolife in a report on Wednesday, May 1st. TheStreet raised Cryolife from a c rating to a b- rating in a research note on Wednesday, May 1st. Canaccord Genuity reaffirmed a buy rating and issued a $35.00 price target (up previously from $32.00) on shares of Cryolife in a research note on Wednesday, May 1st. Zacks Investment Research downgraded Cryolife from a hold rating to a sell rating in a research note on Wednesday, February 20th. Finally, Northland Securities reaffirmed a buy rating and issued a $32.00 price target on shares of Cryolife in a research note on Thursday, January 17th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $31.91.

Shares of CRY traded up $0.04 during midday trading on Wednesday, reaching $30.06. 5,201 shares of the stock were exchanged, compared to its average volume of 201,632. Cryolife has a twelve month low of $23.99 and a twelve month high of $36.05. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.69 and a current ratio of 4.90. The company has a market capitalization of $1.12 billion, a P/E ratio of 115.58 and a beta of 0.54.



Cryolife (NYSE:CRY) last posted its earnings results on Tuesday, April 30th. The medical equipment provider reported $0.04 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.04. Cryolife had a positive return on equity of 3.79% and a negative net margin of 0.09%. The company had revenue of $67.50 million during the quarter, compared to the consensus estimate of $66.37 million. During the same quarter last year, the firm earned $0.02 earnings per share. The company’s revenue was up 9.0% on a year-over-year basis. On average, equities research analysts predict that Cryolife will post 0.31 earnings per share for the current fiscal year.

In related news, VP Jean F. Holloway sold 10,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $31.50, for a total value of $315,000.00. Following the completion of the transaction, the vice president now owns 68,366 shares of the company’s stock, valued at $2,153,529. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Jean F. Holloway sold 8,654 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $32.00, for a total value of $276,928.00. Following the completion of the transaction, the vice president now directly owns 67,020 shares of the company’s stock, valued at approximately $2,144,640. The disclosure for this sale can be found here. In the last ninety days, insiders sold 106,775 shares of company stock valued at $3,325,151. 4.40% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. bought a new position in Cryolife in the fourth quarter valued at about $32,000. Bessemer Group Inc. bought a new position in Cryolife in the fourth quarter valued at about $60,000. LS Investment Advisors LLC grew its position in Cryolife by 126.0% in the fourth quarter. LS Investment Advisors LLC now owns 2,581 shares of the medical equipment provider’s stock valued at $73,000 after acquiring an additional 1,439 shares during the last quarter. US Bancorp DE grew its position in Cryolife by 25.8% in the first quarter. US Bancorp DE now owns 2,540 shares of the medical equipment provider’s stock valued at $74,000 after acquiring an additional 521 shares during the last quarter. Finally, Quantamental Technologies LLC bought a new position in Cryolife in the first quarter valued at about $75,000. Hedge funds and other institutional investors own 71.23% of the company’s stock.

Cryolife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Read More: Net Income

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.